Carmen Berger, MD
Dermatology · Seattle, WANPI 1588749691
Payments from drug & device makers
Across 206 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Novartis$891
- Sanofi$359
- Galderma Laboratories, L.p.$121
- Bristol Myers Squibb$121
- plus $400 from 12 others
What the payments were for
- Speaking & faculty fees$1,47929%
- Food & beverage$3,60071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $1,897 |
| Amgen | 55 | $1,291 |
| Novartis | 51 | $891 |
| Sanofi | 18 | $359 |
| Galderma Laboratories, L.p. | 7 | $121 |
| Bristol Myers Squibb | 17 | $121 |
| Merz North America, Inc. | 2 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Johnson & Johnson | 3 | $42 |
| Lilly USA, LLC | 1 | $33 |
| Dermira, Inc. | 2 | $29 |
| LEO Pharma Inc. | 1 | $23 |
| Botanix SB Inc | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Revance Therapeutics, Inc. | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Biofrontera Inc. | 1 | $14 |
How this compares
$5,079 in reported general payments places this provider in the 75th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $109,088 |
| Tretinoin | 70 | $4,774 |
| Clobetasol Propionate | 104 | $3,712 |
| Calcipotriene | 35 | $3,386 |
| Fluorouracil | 41 | $2,721 |
| Tacrolimus | 23 | $2,165 |
| Minoxidil | 154 | $1,823 |
| ValacyclovirValacyclovir Hcl | 37 | $1,684 |
| Metronidazole | 14 | $781 |
| Ketoconazole | 59 | $684 |
| Fluocinonide | 11 | $420 |
| Triamcinolone Acetonide | 42 | $336 |
| Clotrimazole | 12 | $122 |
| Mupirocin | 19 | $121 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Seattle
- Vivian ShiSeattle$1.1M
- Michi ShinoharaSeattle$277K
- James CollyerSeattle$115K
- Alison YoungSeattle$53K
- Sonja KrejciSeattle$53K
- Paul NghiemSeattle$35K
- Andrew LinSeattle$19K
- John ScopettaSeattle$15K
- Tien NguyenSeattle$13K
- Paula ZookSeattle$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.